N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-N'-hydroxyoctanediamide | 1236199-87-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-N'-hydroxyoctanediamide
• CAS: 1236199-87-3
• 化学式: C₁₇H₂₄F₂N₄O₇
• 分子量: 434.397
• InChiKey: WDABQIOYRUUEGE-VCTAVGKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  161
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  甲基8-氯-8-氧代辛酸 在 N-甲基吗啉 、 吡啶 、 甲醇 、 sodium methylate 、 氯甲酸乙酯 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 26.92h， 生成 N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-N'-hydroxyoctanediamide
  参考文献：
  名称：

  [EN] HYDROXAMIC ACID DERIVATIVES
  [FR] DÉRIVÉS D'ACIDE HYDROXAMIQUE

  摘要：

  公开号：

  WO2010085377A3

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DU CANCER
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2020026054A1

  公开（公告）日：2020-02-06

  The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications.

  公式I和公式II的化合物和化合物包括核酸合成抑制剂共轭物或其多晶形、对映异构体、立体异构体、溶剂合物和水合物。这些共轭物可以制成药物组合物。药物组合物可以制成口服、静脉注射、溶液、糖浆、袋剂、经皮给药或注射剂型。这样的组合物可以用于治疗癌症或其相关并发症。
• Hydroxamic Acid Derivatives
  申请人：Chen Yu

  公开号：US20110269706A1

  公开（公告）日：2011-11-03

  The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
• HYDROXAMIC ACID DERIVATIVES
  申请人：Purdue Pharmaceutical Products L.P.

  公开号：US20140066419A1

  公开（公告）日：2014-03-06

  The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein P, Z, and m are defined herein above.
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
  申请人：Cellix Bio Private Limited

  公开号：US20210171564A1

  公开（公告）日：2021-06-10

  The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications.
• US9096627B2
  申请人：——

  公开号：US9096627B2

  公开（公告）日：2015-08-04